Browse INCENP

Summary
SymbolINCENP
Nameinner centromere protein antigens 135/155kDa
Aliases FLJ31633; inner centromere protein antigens (135kD, 155kD); binds and activates aurora-B and -C in vivo and ......
Chromosomal Location11q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Chromosome, centromere Cytoplasm, cytoskeleton, spindle Midbody Chromosome, centromere, kinetochore Note=Colocalized at synaptonemal complex central element from zygotene up to late pachytene when it begins to relocalize to heterochromatic chromocenters. Colocalizes with AURKB at a connecting strand traversing the centromere region and joining sister kinetochores, in metaphase II centromeres. This strand disappears at the metaphase II/anaphase II transition and relocalizes to the spindle midzone (By similarity). Colocalizes with AURKB at mitotic chromosomes (PubMed:11453556). Localizes to inner kinetochore (PubMed:16760428). Localizes on chromosome arms and inner centromeres from prophase through metaphase and then transferring to the spindle midzone and midbody from anaphase through cytokinesis (PubMed:15316025). Cocalizes to the equatorial cell cortex at anaphase (PubMed:11453556).
Domain PF03941 Inner centromere protein
PF12178 Chromosome passenger complex (CPC) protein INCENP N terminal
Function

Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Acts as a scaffold regulating CPC localization and activity. The C-terminus associates with AURKB or AURKC, the N-terminus associated with BIRC5/survivin and CDCA8/borealin tethers the CPC to the inner centromere, and the microtubule binding activity within the central SAH domain directs AURKB/C toward substrates near microtubules (PubMed:15316025, PubMed:12925766, PubMed:27332895). The flexibility of the SAH domain is proposed to allow AURKB/C to follow substrates on dynamic microtubules while ensuring CPC docking to static chromatin (By similarity). Activates AURKB and AURKC (PubMed:27332895). Required for localization of CBX5 to mitotic centromeres (PubMed:21346195). Controls the kinetochore localization of BUB1 (PubMed:16760428).

> Gene Ontology
 
Biological Process GO:0000819 sister chromatid segregation
GO:0000910 cytokinesis
GO:0007059 chromosome segregation
GO:0007062 sister chromatid cohesion
GO:0007067 mitotic nuclear division
GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0098813 nuclear chromosome segregation
Molecular Function -
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000776 kinetochore
GO:0000777 condensed chromosome kinetochore
GO:0000779 condensed chromosome, centromeric region
GO:0000785 chromatin
GO:0000792 heterochromatin
GO:0000793 condensed chromosome
GO:0000794 condensed nuclear chromosome
GO:0000795 synaptonemal complex
GO:0000800 lateral element
GO:0000801 central element
GO:0005721 pericentric heterochromatin
GO:0005819 spindle
GO:0005874 microtubule
GO:0010369 chromocenter
GO:0030496 midbody
GO:0044454 nuclear chromosome part
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-68886: M Phase
R-HSA-392499: Metabolism of proteins
R-HSA-68882: Mitotic Anaphase
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-68877: Mitotic Prometaphase
R-HSA-597592: Post-translational protein modification
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663220: RHO GTPases Activate Formins
R-HSA-2500257: Resolution of Sister Chromatid Cohesion
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-4615885: SUMOylation of DNA replication proteins
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
Summary
SymbolINCENP
Nameinner centromere protein antigens 135/155kDa
Aliases FLJ31633; inner centromere protein antigens (135kD, 155kD); binds and activates aurora-B and -C in vivo and ......
Chromosomal Location11q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between INCENP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolINCENP
Nameinner centromere protein antigens 135/155kDa
Aliases FLJ31633; inner centromere protein antigens (135kD, 155kD); binds and activates aurora-B and -C in vivo and ......
Chromosomal Location11q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of INCENP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.68 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolINCENP
Nameinner centromere protein antigens 135/155kDa
Aliases FLJ31633; inner centromere protein antigens (135kD, 155kD); binds and activates aurora-B and -C in vivo and ......
Chromosomal Location11q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of INCENP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2260.475
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.9410.538
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3040.81
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3890.329
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6290.748
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0920.972
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3670.299
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2180.877
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6060.682
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9940.288
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0850.461
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.388.81e-06
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of INCENP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolINCENP
Nameinner centromere protein antigens 135/155kDa
Aliases FLJ31633; inner centromere protein antigens (135kD, 155kD); binds and activates aurora-B and -C in vivo and ......
Chromosomal Location11q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of INCENP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolINCENP
Nameinner centromere protein antigens 135/155kDa
Aliases FLJ31633; inner centromere protein antigens (135kD, 155kD); binds and activates aurora-B and -C in vivo and ......
Chromosomal Location11q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of INCENP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by INCENP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolINCENP
Nameinner centromere protein antigens 135/155kDa
Aliases FLJ31633; inner centromere protein antigens (135kD, 155kD); binds and activates aurora-B and -C in vivo and ......
Chromosomal Location11q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of INCENP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolINCENP
Nameinner centromere protein antigens 135/155kDa
Aliases FLJ31633; inner centromere protein antigens (135kD, 155kD); binds and activates aurora-B and -C in vivo and ......
Chromosomal Location11q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of INCENP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolINCENP
Nameinner centromere protein antigens 135/155kDa
Aliases FLJ31633; inner centromere protein antigens (135kD, 155kD); binds and activates aurora-B and -C in vivo and ......
Chromosomal Location11q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between INCENP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolINCENP
Nameinner centromere protein antigens 135/155kDa
Aliases FLJ31633; inner centromere protein antigens (135kD, 155kD); binds and activates aurora-B and -C in vivo and ......
Chromosomal Location11q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting INCENP collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting INCENP.
ID Name Drug Type Targets #Targets
DB07340N~6~-cyclohexyl-N~2~-(4-morpholin-4-ylphenyl)-9H-purine-2,6-diamineSmall MoleculeAURKB, INCENP2